This announcement serves to conclude drug discount contracts in accordance with Section 130a (8) SGB V on the active substance (s) mentioned under point II.1.1). It is not about awarding public contracts within the meaning of Directive 2014/24 / EU or Sections 97 ff GWB. Any pharmaceutical entrepreneur can become a contractual partner in accordance with Section 4 (18) AMG. According to the case law of the CJEU, such approval procedures are not necessarily subject to public procurement law, since there is no competition due to the lack of a selection decision. The announcement serves as an invitation to conclude discount contracts with non-dispositional conditions that apply to all contractual partners, including the determination of the discount. The contract is concluded by signing the contract documents and submitting the required declarations, which can be requested from the contact point named under I.3).

The earliest start of the contract is May 1st, 2021 provided the signed contract and the required declarations have been received by the contact point named under I.3) by April 8th, 2021. The information in IV.2.2) relates to this. In the event of a later receipt, the start of the contract is the 1st of the month following the month in which the signed contract and the required declarations or evidence are received at the contact point named under I.3), provided that the receipt is received by the 5th of each month ; otherwise the 1st of the month after next. The contracts end automatically without the need for termination as soon as contracts are concluded for the active ingredient (s) or the active ingredient combination (s) as part of an award procedure. The contracts end on April 30, 2023.